Eisai Company, Limited

Takatoshi Kawai

Jean-Christophe P Harmange

Mark Spyvee

Kenzo Muramoto

Satoshi Yamamoto

Naoki Yoneda

Tomohiro Matsushima

Makoto Kotake

Yoshiyuki Kawakami

Hong Du

Hiroshi Shirota

Kenichi Chiba

Isao Tanaka

Fabian Gusovsky

Yoshiharu Mizui

Masaki Goto

Hideki Sakurai

Yoshikazu Kuboi

Masanori Fujita

John (Yuan) Wang

Yoshihito Eguchi

Akifumi Kimura

Yong-Chun Shen

Megumi Kawada

Roch Boivin

Yimin Jiang

Xiang-Yi Li

Jesse Chow

Charles-André Lemelin

Takeshi Nagasu

Takashi Owa

Ray Wood

Hiroyuki Kato

Akira Yokoi

Junro Kuromitsu

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

The present invention provides compositions comprising compounds having formula (I): 

The present invention provides compounds having formula (I): 

Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.

Method of testing anticancer agent-sensitivity of tumor cells

Growing community of inventors

Tsukuba, Japan

Takatoshi Kawai